1st Source Bank Named One of America's Best Banks by Forbes
Ranked #26 in Top 100 U.S. Banks
South Bend, Indiana--(Newsfile Corp. - February 27, 2025) - 1st Source Bank (NASDAQ: SRCE) is pleased to announce that they were once again named to Forbes' America's Best Banks list, taking the 26 th spot out of 100. According to Forbes, they look at "10 metrics measuring growth, credit quality and profitability for the 12 months ending September 30, 2024, and stock performance for the 12 months ending January 10, 2025." 1st Source is one of only three banks in Indiana to make this year's list.
"We are honored to receive recognition as one of America's Best Banks for the second year in a row," said Andrea Short, President and CEO of 1st Source Bank and President of 1st Source Corporation. "To rank number 26 on such a prestigious list of competitors is a testament to our colleagues' commitment to living out our mission to help our clients achieve security, build wealth, and realize their dreams. I am proud of our long history of serving our clients well while reinforcing our stability as a financial institution in the areas of growth, credit quality and performance."
The 16 th annual America's Best Banks list is compiled from analyzing the 200 largest publicly traded U.S. banks and thrifts by assets. Forbes lists the 10 equally-weighted financial metrics as "net interest margin; return on average tangible common equity; return on average assets; CET1 ratio; efficiency ratio; nonperforming assets as a percentage of total assets; reserves as a percentage of total assets; risk-based capital ratio; operating revenue growth; and net charge-offs as a percentage of total loans." While S&P Global Market Intelligence provides the data, the rankings are done separately by Forbes. The entire list can be viewed here: Forbes 2025 America's Best Banks.
America's Best Banks
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9536/242671_1stsourceforbes.jpg
1st Source Corporation, parent company of 1st Source Bank, has assets of $8.9 billion and is the largest locally controlled financial institution headquartered in the northern Indiana-southwestern Michigan area. The Corporation includes 77 banking centers, 18 1st Source Bank Specialty Finance Group locations nationwide, nine Trust and Wealth Advisory Services locations, 10 1st Source Insurance offices, and three loan production offices. For more than 160 years, 1st Source has been committed to our mission of helping our clients achieve security, build wealth and realize their dreams. For more information, visit https://www.1stsource.com/.
###
Contact:
Hannah Nichols
NicholsHa@1stsource.com
574-235-2128
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 hours ago
- Globe and Mail
Why AppFolio Stock Rocked the Market on Tuesday
One quite active stock mover on a forgettable Tuesday for the market was specialized business software developer AppFolio (NASDAQ: APPF). The company's shares saw a robust rise of almost 5% across the trading day, thanks to a pair of insider stock buys disclosed in regulatory filings. On that day, the S&P 500 (SNPINDEX: ^GSPC) also rose but by nowhere near as much, inching up to close the day 0.6% higher. A pair of very familiar stock buyers The two AppFolio folks snapping up shares of the company were members of its board of directors, Timothy Bliss and Casey Donald. Of the pair, Bliss was the more assertive, as he amassed 22,000 shares in a series of buys between last Thursday and the following Monday. The per-share price he paid for each of these blocks ranged from $215.28 to $218.73. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » As for Donald, his buying activity was more muted and concentrated. In a single purchase made last Friday, he snapped up 4,000 shares, paying an average of $217.73 apiece for the privilege. Shares of AppFolio, a software-as-a-service (SaaS) company that focuses on the real estate market, have seen something of an upswing lately. In no small part, this is a recovery from a sell-off following the company's first-quarter earnings release, published in late April. Although it posted solid growth on the top line, its net income fell, and it missed analyst estimates for both metrics. Lofty expectations We should bear in mind that investor expectations for the often-prosperous SaaS segment can be awfully high. Often, folks invested in industry titles demand not only strong, across-the-board growth; they insist on crushing beats too. To me, AppFolio is still doing very well in its niche, and remains robustly profitable despite that recent bottom-line dip. I think those insider buys were smart. Should you invest $1,000 in AppFolio right now? Before you buy stock in AppFolio, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AppFolio wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
10 hours ago
- Globe and Mail
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit ('RSU') awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the '2021 Inducement Plan'). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). The 2021 Inducement Plan is used exclusively for granting equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $33.08 per share, which is equal to the closing price of Crinetics' common stock on the Nasdaq Global Select Market on June 10, 2025. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee's continued employment with Crinetics on such vesting dates. The RSUs will vest over four years in equal annual installments beginning on the one-year anniversary of the applicable vesting commencement date, also subject to each employee's continued employment with Crinetics on such vesting dates. The stock option and RSU awards are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of an applicable stock option award agreement or RSU award agreement covering the respective grant. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@ (858) 345-6340
Globe and Mail
12 hours ago
- Globe and Mail
Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead?
Those who invest in shares of Tesla Inc. (NASDAQ: TSLA) know that they are signed up for one of the wildest roller coaster rides in the stock market today, not only because the stock has been historically volatile but also because the company's CEO, Elon Musk, is starting to get involved in other areas that could potentially turn his attention away from what needs to be done to secure Tesla's leadership and future. [content-module:CompanyOverview|NASDAQ:TSLA] As most are aware, Musk has resigned from his role in a special government agency called the Department of Government Efficiency (DOGE, for short). While the intentions were good regarding the type of work this agency was to accomplish, disagreements between Musk and President Trump have driven two opposing views to a volatile week in Tesla stock, leaving some shareholders to incur losses as collateral damage. Seasoned Wall Street participants would see the recent panic as an opportunity in the technology sector, especially for shareholders eyeing lower prices. For Tesla, however, this is where the charts become particularly useful. This is important, especially when viewed through an auction lens, because there is an obvious price that Tesla could reach before providing an optimal entry point. Gaming: The Future of Tesla Now that Musk can focus his energy on Tesla's development, one clear objective will be fulfilled in the coming months and quarters. The race to make the robotaxi dream a reality should return to the CEO's forefront, especially as new competition has entered the scene. Waymo, an autonomous driving platform owned by Alphabet Inc. (NASDAQ: GOOGL), has already made significant progress in this space, averaging up to 250,000 rides per week. Whether it is due to technological superiority, market share, or sheer adoption from end users, Tesla now has a lot of ground to make up in this regard. This is one positive catalyst investors can look forward to today, especially as Musk is set to come back to the ground floor at Tesla. With this in mind, investors should still command a price for the stock that prices out most (if not all) of the potential downside that could arise from this current political feud. With a robotaxi announcement expected in the coming weeks of June 2025, it is high time for investors to strategize their positioning in the stock before the information spreads out more quickly than they can react to it. For this reason, the following technical level should also be kept in mind. Where Tesla Can Be Bought Examining the one-year chart for Tesla, investors can identify a significant inefficiency. During late April 2025, the price jumped aggressively from $259 per share to $288 per share in a matter of hours, creating a pattern that some would call a buy-side imbalance, where the auction left little to no time for investors to enter and chase the upward momentum in price. On a psychological level, this means there are still bulls waiting on the sidelines for this price, making it a mental and emotional anchor for buy orders to be executed again. In fact, the $270 mark represented solid support due to this development, where impatient buyers couldn't wait to retest the lower end of the breakout and had to get in. After falling by roughly 15% in one week, the $270 area acted as a backstop for further selling, accurately fulfilling this technical and psychological setup. Therefore, those looking to buy have two choices from today's $295 per share price. One option is to make room for the price to move up toward the $310 mark again, where the opposite pattern formed. On the way down, numerous sell-side inefficiencies formed, as a fast auction didn't allow sellers to exit and cut their losses. Given the uncertainty, it wouldn't be too far from reality to expect these beaten-down bulls to revisit that price before letting go of their shares. [content-module:TradingView|NASDAQ:TSLA] So now investors can watch the reaction in Tesla's price in this range; if it continues to act as 'resistance,' then they can rest assured that the lower price area near $270 will be tested again. At this point, they will have another incentive to open new positions on the long side. Here's a good sign that supports this view: up to $20 billion of institutional buying took place over the recent quarter for Tesla stock, a period that overlaps with this inefficiency, with the stock reaching the $270 mark, indicating a footprint of institutional liquidity advantages being taken. The map is laid out, and at 60% of its 52-week high, Tesla stock offers new investors a great risk-to-reward ratio moving forward, especially with a new $500 per share price target set by Dan Ives, an analyst from Wedbush Securities as of early June 2025. In his view, Tesla promises a rally of up to 70% from its current level. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...
